The Phenotyping Core will provide ORDRCC investigators with access to advanced high-content, cutting-edge biomolecular phenotyping services and datasets spanning genetic, genomic, proteomic, and functional cellular bioresponses on clinical samples available through the Clinical Characterization and Biorepository Core (CCBC) or from other ORDRCC Investigator projects. The tight integration of the Phenotyping Core and the CCBC within the ORDRCC enables both the efficient performance of phenotype characterizations and correlation of the clinical characteristics with molecular or cellular phenotypes on specific clinical samples. Consolidation of the range of technologies required for the complete characterization of a molecular or cellular phenotype into a single Core allows the Core to better assist all ORDRCC investigators in the efficient planning/design, execution and data analysis as dictated by their individual project needs. The Core is able to provide experience in performing research using clinical specimens, the necessary technical expertise in a wide range of molecular and bioassays, access to equipment and resources enabling cutting-edge approaches to address research questions, quality control assessment of the data collected and data processing suitable for higher end statistical modeling of phenotype/clinical associations. Therefore, the goals of the Phenotyping Core can be summarized as follows: Goal 1: Offer expert consulting for experimental project design, cost analysis, implementation planning and project management for ORDRCC investigators. Goal 2: Provide access to advanced technology, centralized equipment and experienced personnel for high throughput/high content experimental phenotype characterization and biomarker assays in genetic, genomic, proteomic, immune phenotype and immune functional domains. Goal 3: Supply guidance on data quality control, processing of raw data, and preparation of data sets for more extensive statistical modeling. Goal 4: Assess and develop new cutting edge technologies for phenotype characterization.

Public Health Relevance

This Phenotyping Core provides ORDRCC investigators access to the technical expertise and resources to perform genetic, genomic, proteomic and cellular phenotype/function biomarker analyses required to develop a world class rheumatic disease focused clinical-translational research career.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Center Core Grants (P30)
Project #
2P30AR053483-06
Application #
8444002
Study Section
Special Emphasis Panel (ZAR1-KM (M1))
Project Start
Project End
Budget Start
2012-09-01
Budget End
2013-08-31
Support Year
6
Fiscal Year
2012
Total Cost
$383,381
Indirect Cost
$155,178
Name
Oklahoma Medical Research Foundation
Department
Type
DUNS #
077333797
City
Oklahoma City
State
OK
Country
United States
Zip Code
73104
Pelikan, Richard C; Kelly, Jennifer A; Fu, Yao et al. (2018) Enhancer histone-QTLs are enriched on autoimmune risk haplotypes and influence gene expression within chromatin networks. Nat Commun 9:2905
Patel, Zubin; Lu, Xiaoming; Miller, Daniel et al. (2018) A plausibly causal functional lupus-associated risk variant in the STAT1-STAT4 locus. Hum Mol Genet :
Kheir, Joseph M; Guthridge, Carla J; Johnston, Jonathon R et al. (2018) Unique clinical characteristics, autoantibodies and medication use in Native American patients with systemic lupus erythematosus. Lupus Sci Med 5:e000247
Young, K A; Munroe, M E; Harley, J B et al. (2018) Less than 7 hours of sleep per night is associated with transitioning to systemic lupus erythematosus. Lupus 27:1524-1531
Jog, Neelakshi R; Chakravarty, Eliza F; Guthridge, Joel M et al. (2018) Epstein Barr Virus Interleukin 10 Suppresses Anti-inflammatory Phenotype in Human Monocytes. Front Immunol 9:2198
Hanscombe, Ken B; Morris, David L; Noble, Janelle A et al. (2018) Genetic fine mapping of systemic lupus erythematosus MHC associations in Europeans and African Americans. Hum Mol Genet 27:3813-3824
Bagavant, Harini; Dunkleberger, Micah L; Wolska, Nina et al. (2018) Antibodies to periodontogenic bacteria are associated with higher disease activity in lupus patients. Clin Exp Rheumatol :
Scofield, R Hal; Sharma, Rohan; Harris, Valerie M (2018) Reply. Arthritis Rheumatol 70:626-627
Glauzy, Salomé; Boccitto, Marco; Bannock, Jason M et al. (2018) Accumulation of Antigen-Driven Lymphoproliferations in Complement Receptor 2/CD21-/low B Cells From Patients With Sjögren's Syndrome. Arthritis Rheumatol 70:298-307
St Clair, E William; Baer, Alan N; Wei, Chungwen et al. (2018) Clinical Efficacy and Safety of Baminercept, a Lymphotoxin ? Receptor Fusion Protein, in Primary Sjögren's Syndrome: Results From a Phase II Randomized, Double-Blind, Placebo-Controlled Trial. Arthritis Rheumatol 70:1470-1480

Showing the most recent 10 out of 284 publications